Displaying drugs 10751 - 10775 of 11552 in total
CEQ508
CEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.
Investigational
Matched Description: … CEQ508 is a Live Attenuated E. …
Vamikibart
Vamikibart is under investigation in clinical trial NCT05642312 (A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema).
Investigational
Matched Description: … Vamikibart is under investigation in clinical trial NCT05642312 (A Study to Investigate Vamikibart in …
2,2':6',2''-Terpyridine Platinum(Ii)
2,2':6',2''-terpyridine Platinum(Ii) is a solid. Known drug targets of 2,2':6',2''-Terpyridine Platinum(Ii) include truncated transposase and autolysin.
Experimental
Matched Description: … 2,2':6',2''-terpyridine Platinum(Ii) is a solid. …
Veltuzumab
Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
Investigational
Matched Description: … Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials …
Sarafloxacin
Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.
Vet approved
Withdrawn
Matched Description: … Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories …
Prasinezumab
Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
Investigational
Matched Description: … Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of …
PF-04937319
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Matched Description: … PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics …
BMS-791826
BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).
Investigational
Matched Description: … BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and …
PF-06650833
PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Investigational
Matched Description: … 06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A …
RO-6870810
RO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Matched Description: … RO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants …
Recombinant Super-Compound Interferon
Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.
Investigational
Matched Description: … Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified …
Itolizumab
Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Investigational
Matched Description: … Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and …
Olvimulogene nanivacirepvec
Olvimulogene nanivacirepvec is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).
Investigational
Matched Description: … Olvimulogene nanivacirepvec is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, …
PR006
PR006 is a non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene. It is being investigated for the treatment of dementia.
Investigational
Matched Description: … PR006 is a non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene …
OS2966
OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.[A254561, L47351]
Investigational
Matched Description: … OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute …
F6-734
F6-734 is a bispecific monoclonal antibody with affinity for anticarcinoembryonic antigen (CEA) and anti-diethylenetriamine pentaacetic acid (DTPA) (hMN-14 × m734).[A255217,A255222]
Investigational
Matched Description: … F6-734 is a bispecific monoclonal antibody with affinity for anticarcinoembryonic antigen (CEA) and anti-diethylenetriamine …
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
Matched Description: … CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. …
MOD-5014
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
Matched Description: … MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. …
HOV-12020
HOV-12020 is a palm tocotrienols complex being investigated for the treatment of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
Investigational
Matched Description: … HOV-12020 is a palm tocotrienols complex being investigated for the treatment of cerebral autosomal-dominant …
Povorcitinib
Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)).
Investigational
Matched Description: … Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety …
Ecnoglutide
Ecnoglutide is under investigation in clinical trial NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity).
Investigational
Matched Description: … Ecnoglutide is under investigation in clinical trial NCT05813795 (A Phase 3 Study to Evaluate the Efficacy …
XL820
XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of...
Investigational
Matched Description: … XL820 is a solid. ... receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a …
Sparteine
Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one...
Experimental
Withdrawn
Matched Description: … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. ... Sparteine is a plant alkaloid derived from _Cytisus scoparius_ and _Lupinus mutabilis_ which may chelate …
Cirazoline
Cirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent.
Cirazoline has also been shown to decrease food...
Experimental
Matched Description: … Cirazoline acts on a number of α adrenergic receptors. ... It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. …
SCB-2019
SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture.
The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. As of June 2020, the company is pursuing a...
Investigational
Matched Description: … SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID ... As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908 …
Displaying drugs 10751 - 10775 of 11552 in total